Takura’s executive chairman Per Båtelson presented the group on Stockholm Corporate Finance Financial Hearing today. The presentation and QA is 30 minutes and gives a high level overview of the group.
Takura has acquired all shares in clinical stage immuno-oncology company Polybiocept GmbH (PBC). Takura was already a minority owner in the company which owns a patent portfolio for TIL (tumor infiltrating lymphocytes) therapy. Immunotherapy is one of the fastest growing segments in the pharmaceutical industry and has the potential to revolutionize cancer care. PBC has a collaboration with Krankenhaus Nordwest (KHNW) in Frankfurt where 16 patients with solid cancers have been treated with PBC’s technology under hospital exemption. The company has now started to plan for a phase I clinical trial.
Takura is a Swedish company that commercializes advanced cell therapy research in order to accelerate the development and make groundbreaking treatments accessible and more affordable.